Cambridge, United Kingdom

Erika Morizzo

This inventor holds 2 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignee: N.V., Ablynx. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Erika Morizzo. Retrieved from https://idiyas.com/inventor/erika-morizzo-h7penke1

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Erika Morizzo

Introduction

Erika Morizzo is an accomplished inventor based in Cambridge, GB. She currently works at Ablynx N.V., where she focuses on developing innovative solutions in the field of biochemistry. Although she has not yet been granted any patents, her work is significant in advancing scientific knowledge and applications.

Latest Patent Applications

Erika's latest patent applications include "Serum Albumin Binders." This invention relates to amino acid sequences that can bind to serum albumin. In particular, it focuses on immunoglobulin single variable domains, specifically heavy-chain immunoglobulin single variable domains, that can bind to serum albumin. The invention also encompasses proteins, polypeptides, and other constructs, compounds, molecules, or chemical entities that include at least one of the immunoglobulin single variable domains binding to serum albumin.

Conclusion

Erika Morizzo is a promising inventor whose work in serum albumin binders showcases her potential in the field of biochemistry. Her contributions may lead to significant advancements in medical and scientific applications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…